Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data
Gils Roex,
Tom Feys,
Yves Beguin,
Tessa Kerre,
Xavier Poiré,
Philippe Lewalle,
Peter Vandenberghe,
Dominique Bron,
Sébastien Anguille
Affiliations
Gils Roex
Tumor Immunology Group, Laboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, 2650 Edegem, Belgium
Tom Feys
Ariez International BV, 9000 Ghent, Belgium
Yves Beguin
Department of Hematology, University of Liège, 4000 Liège, Belgium
Tessa Kerre
Department of Hematology, University Hospital Ghent, 9000 Ghent, Belgium
Xavier Poiré
Faculty of Medicine and Dentistry, Université Catholique de Louvain, 1200 Woluwe-Saint-Lambert, Belgium
Philippe Lewalle
Department of Hematology, Institut Jules Bordet, 1000 Brussels, Belgium
Peter Vandenberghe
Department of Hematology, University Hospitals Leuven, 3000 Leuven, Belgium
Dominique Bron
Department of Hematology, Institut Jules Bordet, 1000 Brussels, Belgium
Sébastien Anguille
Tumor Immunology Group, Laboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, 2650 Edegem, Belgium
Chimeric antigen receptor (CAR)-T-cell therapy is an innovative form of adoptive cell therapy that has revolutionized the treatment of certain hematological malignancies, including B-cell non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia (ALL). The treatment is currently also being studied in other B-cell neoplasms, including multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). CD19 and B-cell maturation antigen (BCMA) have been the most popular target antigens for CAR-T-cell immunotherapy of these malignancies. This review will discuss the efficacy and toxicity data from the pivotal clinical studies of CD19- and BCMA-targeted CAR-T-cell therapies in relapsed/refractory B-cell malignancies (NHL, ALL, CLL) and MM, respectively.
